Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 symbols : Lly save search
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Published: 2023-05-04 (Crawled : 12:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.06%
H: 0.29%
C: -0.7%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.0%
covid-19 fda sabizabulin treatment risk trial agreement
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
Published: 2023-04-04 (Crawled : 14:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.72%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 7.89%
H: 1.63%
C: -9.76%
covid-19 sabizabulin respiratory update preclinical program results
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-26 (Crawled : 13:20) - prnewswire.com
GILD | News | $66.33 0.26% 2.8M
|
Health Technology
| Email alert
Add to watchlist
NVO | $123.01 0.21% 2.6M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.81 1.65% 15M
|
Health Technology
| Email alert
Add to watchlist
SYNH | $42.98 0.0% 7.4M
|
Health Services
| Email alert
Add to watchlist
ICLR | $288.325 -1.2% 170K
|
Health Technology
| Email alert
Add to watchlist
LLY | $727.48 -2.48% 2M
|
Health Technology
| Email alert
Add to watchlist
covid-19 trials research global report hiv impact study market
Non-steroidal Anti-inflammatory Drugs Market Research Report by Disease Indication, Drugs, Route of Administration, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-07 (Crawled : 16:00) - prnewswire.com
RBGPF | $51.61 4.7K
|
Consumer Non-Durables
|
| O: 0.06%
H: 3.15%
C: 0.15%
GLAXF | $20.2 510
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -6.74%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: -4.28%
AZNCF | $138.24 800
|
Health Technology
|
| O: -0.56%
H: 0.61%
C: 0.01%
RBGLY | $10.35 990K
|
Manufacturing
|
| O: 0.51%
H: 0.48%
C: -0.14%
VTRS | $11.23 0.99% 1.5M
|
Health Technology
|
| O: 0.0%
H: 0.55%
C: -0.27%
ZTS | News | $147.61 -3.59% 2.5M
|
Health Technology
|
| O: -0.06%
H: 0.54%
C: -1.77%
PRGO | $30.49 1.84% 350K
|
Health Technology
|
| O: -0.09%
H: 0.47%
C: -0.28%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: -0.98%
H: 0.24%
C: -1.78%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.21%
H: 1.6%
C: 0.72%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 5.18%
H: 0.0%
C: 0.0%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
covid-19 research global disease report impact distribution market
Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-11-10 (Crawled : 02:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 1.09%
H: 0.48%
C: 0.4%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -58.83%
H: 25.89%
C: 12.78%
covid-19 fda risk sabizabulin meeting respiratory authorization update
Pediatric Health Market Research Report by Type, Therapeutics, Treatment, Treatment Type, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-03 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
AZNCF | $138.24 800
|
Health Technology
|
| O: -1.02%
H: 2.67%
C: 0.18%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.28%
H: 0.0%
C: 0.0%
VTRS | $11.23 0.99% 1.5M
|
Health Technology
|
| O: 0.83%
H: 1.33%
C: -0.51%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 1.13%
H: 0.63%
C: 0.53%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.97%
H: 0.18%
C: -2.13%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.42%
H: 0.59%
C: -0.04%
ABT | News | $106.76 1.42% 3.8M
|
Health Technology
|
| O: 1.43%
H: 0.41%
C: 0.25%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
GILD | News | $66.33 0.26% 2.8M
|
Health Technology
|
| O: -0.4%
H: 2.75%
C: 1.52%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.72%
H: 1.29%
C: 1.04%
covid-19 treatment research global report impact health market
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 1.01%
H: 2.19%
C: 1.07%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 0.63%
H: 0.6%
C: -3.2%
covid-19 treatment sabizabulin disease oxygen week presentation
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk
Published: 2022-09-19 (Crawled : 17:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.78%
H: 0.01%
C: -0.45%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -5.6%
H: 0.74%
C: -13.28%
covid-19 fda risk sabizabulin meeting review authorization
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-09-19 (Crawled : 17:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.78%
H: 0.01%
C: -0.45%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -5.6%
H: 0.74%
C: -13.28%
covid-19 fda risk sabizabulin meeting respiratory review authorization
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-09-07 (Crawled : 18:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.64%
H: 1.18%
C: 0.92%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 9.6%
H: 3.38%
C: -28.02%
covid-19 fda risk sabizabulin meeting respiratory review authorization
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
Published: 2022-08-22 (Crawled : 13:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.15%
H: 1.08%
C: 0.25%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 5.44%
H: 3.53%
C: -7.93%
covid-19 treatment sabizabulin granted
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
Published: 2022-08-19 (Crawled : 13:00) - globenewswire.com
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.25%
H: 2.6%
C: 1.66%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -3.19%
H: 7.78%
C: -3.37%
covid-19 disease international
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-08-09 (Crawled : 15:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.86%
H: 0.53%
C: -0.68%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -0.5%
H: 2.25%
C: -4.17%
covid-19 treatment risk sabizabulin respiratory presentation study
European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries
Published: 2022-07-27 (Crawled : 15:20) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.78%
H: 0.57%
C: -0.01%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 0.81%
H: 3.05%
C: 1.2%
covid-19 treatment sabizabulin review initiated
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
Published: 2022-07-25 (Crawled : 12:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: 0.85%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 3.41%
H: 0.07%
C: -8.65%
covid-19 treatment sabizabulin application review authorization
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
Published: 2022-06-29 (Crawled : 11:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -2.65%
H: 2.06%
C: 1.52%
covid-19 treatment ongoing
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
Published: 2022-06-07 (Crawled : 11:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -2.57%
H: 17.21%
C: 13.21%
covid-19 fda risk drug antiviral application authorization emergency use authorization
Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients
Published: 2022-05-18 (Crawled : 17:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: 2.18%
H: 2.7%
C: -5.83%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: 0.0%
covid-19 disease
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization
Published: 2022-05-12 (Crawled : 11:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.09%
H: 3.06%
C: 2.99%
VERU | $1.365 -3.87% 1.7M
|
Health Technology
|
| O: -24.43%
H: 26.44%
C: 23.7%
covid-19 sabizabulin authorization emergency use authorization
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
AULT | $0.2998 23.83% 53M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.